NXP900

Our results show that the multitargeted SRC TKI dasatinib significantly enhanced the efficacy of RET TKIs in RET fusion-positive (RET+) NSCLC and PTC cells...Importantly, synergy was also observed with eCF506 (NXP900), a next-generation clinical SRC inhibitor. Finally, both SRC TKIs restored sensitivity in selpercatinib-resistant RET+ PTC cells. These results elucidate RET and SRC signaling crosstalk in RET+ NSCLC and PTC, suggesting that co-inhibiting SRC has clinical potential in TKI-naïve and -resistant RET+ cancers.

P1, N=140, Recruiting, Nuvectis Pharma, Inc. | N=40 --> 140 | Trial completion date: May 2025 --> Jul 2027 | Trial primary completion date: Apr 2025 --> Mar 2027

P1, N=40, Recruiting, Nuvectis Pharma, Inc. | Trial primary completion date: Jan 2025 --> Apr 2025

P1, N=40, Recruiting, Nuvectis Pharma, Inc. | Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Sep 2024 --> Jan 2025

Application of kinase activity prediction algorithms and interrogation of gene dependency and drug sensitivity databases predicted that the mechanistic target of rapamycin kinase (mTOR) and dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) represented potential therapeutic targets for the EMT and metabolism subtypes, respectively, and this was confirmed using selective inhibitors. Overall, our study provides novel, in-depth insights into GC proteomics, kinomics, and molecular taxonomy and reveals potential therapeutic targets that could provide the basis for precision treatments.

P1, N=40, Recruiting, Nuvectis Pharma, Inc. | Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023

P1, N=40, Not yet recruiting, Nuvectis Pharma, Inc.